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Losartan Metabolite EXP3179 Blocks NADPH
Oxidase-Mediated Superoxide Production by Inhibiting
Protein Kinase C
Potential Clinical Implications in Hypertension
Ana Fortun˜o, Julen Bidegain, Pablo A. Robador, Jose´ Hermida, Jacinto Lo´pez-Sagaseta, Oscar Beloqui,
Javier Díez, Guillermo Zalba
Abstract—Oxidative stress plays a critical role in the pathogenesis of hypertension. The NADPH oxidase constitutes a
major source of superoxide anion in phagocytic cells, and its activation is associated with matrix metalloproteinase
(MMP)-9 secretion by these cells. We investigated the effects of the angiotensin II type 1 receptor antagonist losartan
and its metabolites (EXP3174 and EXP3179) on NADPH oxidase activity and MMP-9 secretion in human phagocytic
cells. EXP3179, but not losartan and EXP3174, dose-dependently inhibited (P0.05) phorbol myristate acetate and
insulin-stimulated NADPH oxidase activity. EXP3179 also inhibited phorbol myristate acetate–induced NADPH
oxidase in endothelial cells. In addition, EXP3179 inhibited (P0.05) both phorbol myristate acetate–stimulated
p47phox translocation from cytosol to membranes and protein kinase C activity. Affinity experiments and enzymatic
assays confirmed that EXP3179 inhibited several protein kinase C isoforms. EXP3179 also inhibited (P0.05) phorbol
myristate acetate–stimulated MMP-9 secretion. In a study performed in 153 hypertensive patients, phagocytic NADPH
oxidase activity was lower (P0.05) in losartan-treated compared with untreated patients and in patients treated with
other angiotensin II type 1 receptor antagonists or with angiotensin-converting enzyme inhibitors. Plasma levels of
MMP-9 were lower (P0.05) in losartan-treated hypertensives compared with the other group of patients. Thus,
EXP3179 acts as a blocker of the NADPH oxidase in phagocytic cells by a potential mechanism that targets the protein
kinase C signaling pathway. This effect can be involved in reduced MMP-9 secretion by these cells. It is proposed that
the EXP3179 metabolite may confer to losartan the specific capacity to reduce oxidative stress mediated by phagocytic
cells in hypertensive patients. (Hypertension. 2009;54:744-750.)
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Oxidative stress induced by reactive oxygen species,including superoxide anion (O2 ), is increased in arte-
rial hypertension.1,2 The NADPH oxidase systems constitute
a major source of O2 in the vessel wall, and they are present
in endothelial cells, smooth muscle cells, fibroblasts, and
infiltrated monocytes/macrophages.3,4 Protein kinase C
(PKC)–dependent p47phox phosphorylation and transloca-
tion are major mechanisms involved in phagocytic NADPH
oxidase activation.3 Phagocytic NADPH oxidase is overacti-
vated in essential hypertension.5,6 Clinical studies have dem-
onstrated that treatment with losartan improves endothelial
function and decreases blood pressure through a reduction in
oxidative stress.7,8 Moreover, several experimental studies have
demonstrated beneficial effects of losartan treatment on vascular
alterations by blocking NADPH oxidase activation.9–12
Losartan is hepatically metabolized by the cytochrome-
P450 pathway and exerts its antihypertensive actions predom-
inantly by EXP3174, its main metabolite and the pharmaco-
logical blocker of the angiotensin II type 1 receptor
(AT1R).13,14 Interestingly, during losartan metabolism, the
liver also produces the EXP3179 metabolite, which has no
AT1R-blocking properties.14,15 In recent years, several studies
have reported that the EXP3179 metabolite exerts AT1R-
independent actions.15–18 Kra¨mer et al15 demonstrated that
EXP3179 mediates the anti-inflammatory properties of losar-
tan by abolishing cyclooxygenase-2 upregulation. Further-
more, EXP3179 stimulates endothelial NO synthase and
suppresses tumor necrosis factor-–induced apoptosis.16
Schupp et al17 have demonstrated that EXP3179 acts as a
peroxisome proliferator–activated receptor- agonist. Finally,
the ability of EXP3179 to inhibit collagen-dependent platelet
activation has also been described.18
Therefore, we hypothesized that EXP3179 metabolite
might inhibit NADPH oxidase in phagocytic cells by AT1R-
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independent mechanisms. To test this hypothesis, we ana-
lyzed the ability of losartan and its metabolites, as well as
other drugs interfering with the renin-angiotensin system, to
block NADPH oxidase–dependent O2 production in human
phagocytic cells. Given that matrix metalloproteinase
(MMP)-9 secretion by phagocytic cells is regulated by
NADPH oxidase,19 we also assessed the effect of EXP3179
on this proteolytic enzyme. In addition, we evaluated
NADPH oxidase–dependent O2 production and MMP-9
levels in phagocytic cells and plasma, respectively, obtained
from hypertensive patients treated with different classes of
drugs interfering with the renin-angiotensin system, including
losartan.
Methods
Subjects
The study was performed in 2 different populations. The first
population consisted of 50 apparently healthy subjects in whom the
effect of different drugs that interfere with the renin-angiotensin
system was analyzed on NADPH oxidase–dependent O2 produc-
tion from phagocytic cells. In addition, the effect of EXP3179 was
analyzed on phorbol myristate acetate (PMA)-induced p47phox
translocation, PKC activity, and MMP-9 secretion. The second
population consisted of 153 patients with the diagnosis of essential
hypertension. These patients were considered hypertensive if they
had sitting systolic and/or diastolic blood pressures of 139 and
89 mm Hg, respectively, or if they were taking antihypertensive
medication during 6 months before the study. Blood pressure was
measured on 3 occasions using a mercury sphygmomanometer, and
the mean of these 3 readings was recorded. In this study, NADPH
oxidase–dependent O2 production by phagocytic cells and plasma
MMP-9 levels were evaluated in the patients classified in 4 groups:
untreated patients, patients treated with losartan, patients treated with
other AT1R antagonists (ARAs) different from losartan, and patients
treated with angiotensin-converting enzyme inhibitors (ACEIs).
Both populations consisted of subjects who were referred to our
institution for global cardiovascular risk assessment. Following
institutional guidelines, the subjects were aware of the research
nature of the study, and written informed consent was obtained from
all of them. The study was performed in accordance with the
Declaration of Helsinki, and the local committee on human research
approved of the study protocol.
Determination of NADPH Oxidase–Dependent
O2 Production
Peripheral blood mononuclear cells (PBMCs) were isolated with
Lymphoprep from blood samples. The methodology used to isolate
mononuclear cells yielded preparations with a very high purity
(>99% were lymphocytes and monocytes). NADPH oxidase–de-
pendent O2 production was measured by using 5 mol/L of
lucigenin by a chemiluminescent method. Luminescence was mea-
sured in 400 000 cells every 15 to 30 s along an interval of 1 hour in
a plate reader luminometer (Luminoskan Ascent, Labsystem). A
buffer blank was subtracted from each reading, and the value of the
area under the curve was used to quantify chemiluminescence. Data
are expressed as relative light units produced per second. Although
lucigenin concentration was low enough to avoid autoxidation, the
measurements were validated against an independent measurement
of O2 production using O2 dismutase–inhibitable ferricyto-
chrome C reduction, as reported previously.6 Previous experiments
performed by our group allow us to confirm that NADPH oxidase is
the main source of O2 production in response to PMA stimulation
in phagocytic cells.6,19
Phagocytic NADPH oxidase–dependent O2 production in re-
sponse to 3.2 mol/L of PMA in the presence (20 minutes of
preincubation) of different doses of losartan, EXP3174, and
EXP3179 was evaluated. In some experiments, the effects of
irbesartan, another ARA, and the effect of quinapril, an ACEI,
were also evaluated. In addition, in some experiments, the effect
of 100 nmol/L of human recombinant insulin on NADPH oxi-
dase– dependent O2 production was evaluated in the presence
(20 minutes of preincubation) of different doses of losartan,
EXP3174, and EXP3179. Within the study performed in the
hypertensive population, PMA-stimulated O2 production was
also determined in PBMCs, following the same chemiluminescent
methodology.
Finally, and to test whether EXP3179 could act as an O2
scavenger, we determined O2 production in a homogenate of
protein from the rat kidney in the absence and presence of EXP3179.
Briefly, we determined the effect of 100 mol/L of EXP3179 on
O2 production from 100 g of renal homogenate in the presence of
5 mol/L of lucigenin during 5 minutes. In these experiments, we
used as a positive control for the scavenging of O2 , 100 U/mL of
O2 dismutase.
An expanded Methods section is available in the online Data
Supplement at http://hyper.ahajournals.org.
Results
EXP3179 Metabolite Blocks O2 Production
EXP3179 dose-dependently inhibited PMA-stimulated
NADPH oxidase–mediated O2 production, reaching a sig-
nificant effect at a concentration of 10 mol/L (Figure 1).
The EC50 of this metabolite for PMA-stimulated NADPH
oxidase–mediated O2 production was 30 mol/L. In con-
trast, neither losartan nor EXP3174 influenced PMA-
stimulated NADPH oxidase–mediated O2 production (Fig-
ure 1). Similarly, neither quinapril nor irbesartan influenced
PMA-stimulated NADPH oxidase–dependent O2 produc-
tion (Figure 2).
EXP3179 also inhibited insulin-stimulated NADPH oxi-
dase–mediated O2 production in a dose-dependent way,
reaching a significant effect at a concentration of 50 mol/L
(Figure S1). The EC50 of this metabolite for NADPH oxi-
dase–dependent O2 production was 80 mol/L. In contrast,
EXP3174 did not influence insulin-stimulated NADPH oxi-
dase–dependent O2 production, and losartan exerted an
inhibitory effect that only was statistically significant at a
very high dose (500 mol/L).
To examine whether EXP3179 inhibited O2 production
stimulated by another agonist that is known to activate
NADPH oxidase through PKC, PBMCs were stimulated with
50 ng/L of tumor necrosis factor-. Interestingly, tumor
necrosis factor-–stimulated O2 production was signifi-
cantly reduced in the presence of 100 mol/L of EXP3179
(Figure S2).
Finally, and to test the effect of EXP3179 on NADPH oxidase
activity in vascular cells, several experiments were performed in
the human endothelial cell line, Eahy926. Interestingly,
100 mol/L of EXP3179 significantly (P0.01) reduced PMA-
induced NADPH oxidase activity (Figure S3).
To test whether EXP3179 could act as an O2 scavenger,
we determined O2 production in a protein homogenate in
the absence and presence of EXP3179. Given that O2 levels
were not diminished in the presence of EXP3179 (Figure S4),
we can discard a relevant role of EXP3179 as an O2
scavenger.
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EXP3179 Metabolite Blocks
p47phox Translocation
An important early step in the activation of the phagocytic
NADPH oxidase is the translocation of the cytosolic subunits
to membranes. Thus, after PMA stimulation, an increased
signal for the p47phox protein expression in the membrane
was observed (Figure 3). However, when cells were preincu-
bated with EXP3179, the p47phox translocation induced by
PMA was inhibited (P0.05), thus suggesting that the
EXP3179 metabolite may interfere with some of the mecha-
nisms involved in this necessary step for the activation of the
NADPH oxidase.
EXP3179 Metabolite Inhibits PKC
Given that PKC is a relevant activator of NADPH oxidase in
phagocytic cells,3 the effect of EXP3179 on PMA-stimulated
PKC activity was analyzed in PBMCs. As shown in Figure 4,
PKC activity was enhanced in PMA-stimulated cells. Inter-
estingly, EXP3179 completely inhibited (P0.05) PKC ac-
tivity stimulated by PMA in these cells. Thus, we investigated
the capacity of EXP3179 to bind to human recombinant
PKC by surface plasmon resonance. As shown in Figure
5A, binding of EXP3179 to PKC is clear and concentration
dependent. We plotted the different EXP3179 concentrations
against the corresponding binding responses at equilibrium.
To analyze whether the physical interaction between
EXP3179 and PKC would exert a functional effect, we
studied the effect of EXP3179 in enzymatic assays and we
observed that EXP3179 inhibited (P0.05) the kinase activ-
ity of recombinant PKC. The inhibitory effect of EXP3179
on PKC activity was in the same range as those observed for
bisindolyl maleimide (Figure 5B). Additional experiments
demonstrated that EXP3179 also interacted with the PKC
isoform and reduced its enzymatic activity (Figure S5).
EXP3179 Metabolite Blocks MMP-9 Secretion in
Phagocytic Cells
The effect of EXP3179 on MMP-9 secretion was analyzed in
human monocytes and PBMCs. EXP3179 inhibited (P0.05)
PMA-induced MMP-9 secretion in the 2 types of cellular
preparations (Figure 6).
NADPH Oxidase-Mediated O2 Production and
MMP-9 Levels Are Reduced in Losartan-Treated
Hypertensive Patients
The demographic and clinical characteristics of the patients
included in this study are summarized in the Table. No
differences in blood pressure and other general clinical and
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Figure 1. Effects of (A) EXP3179, (B) EXP3174, and (C) losartan on PMA-induced phagocytic NADPH oxidase–dependent O2
 produc-
tion. Phagocytic cells (4105 PBMCs) were stimulated with 3.2 mol/L of PMA in the absence or presence of different concentrations
of losartan and its metabolites. Values are meanSEM from 25 apparently healthy subjects. *P0.05 vs response to PMA.
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Figure 2. Effects of (A) quinapril and (B)
irbesartan on PMA-induced phagocytic
NADPH oxidase-dependent O2
 produc-
tion. Phagocytic cells (4105 PBMCs)
were stimulated with 3.2 mol/L of PMA
in the absence or presence of different
concentrations of both antihypertensive
drugs. Values are meanSEM from 10
apparently healthy subjects. *P0.05 vs
response to PMA.
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biochemical parameters were found among the 3 subgroups
of treated patients.
NADPH oxidase–dependent O2 production induced by
PMA was lower (P0.05) in patients treated with losartan
than in untreated hypertensives and patients treated with other
ARAs or with ACEIs (Figure 7A). PMA-induced NADPH
oxidase–dependent O2 production measured in patients
treated with other ARAs or with ACEIs was similar to that
measured in untreated patients (Figure 7A).
Plasma levels of MMP-9 were lower (P0.05) in patients
treated with losartan than in untreated patients and patients
treated with other ARAs or with ACEIs (Figure 7B). In
addition, plasma levels of MMP-9 measured in patients
treated with other ARAs or with ACEIs were similar to those
measured in untreated patients (Figure 7B). A positive
correlation (P0.01) was observed between plasma levels of
MMP-9 and NADPH oxidase–dependent O2 production in
the overall population (Figure 7C), which remained signifi-
cant after controlling for age and sex (r0.340; P0.01).
Discussion
The major findings of this study are that EXP3179 inhibits
NADPH oxidase and PKC activities, as well as MMP-9
secretion, in stimulated human phagocytic cells. In addition,
NADPH oxidase activity and plasma levels of MMP-9 were
lower in hypertensive patients treated with losartan than in
untreated hypertensive patients and hypertensive patients
treated with other ARAs and with ACEIs.
It has been proposed that inhibition of phagocytic NADPH
oxidase–dependent O2 production may represent a novel
pharmacological target in the treatment of cardiovascular
diseases.20–22 In this regard, we described for the first time
that EXP3179 inhibits the NADPH oxidase–dependent O2
production in phagocytic cells. Several arguments suggest
that this effect of EXP3179 is independent of the AT1R. First,
the pharmacological profile of losartan metabolites indicates
that the EXP3179 is not related to the antagonism of the
AT1R.13,14,23 Second, neither losartan nor EXP3174 inhibited
NADPH oxidase–dependent O2 production in phagocytic
cells. Lastly, neither irbesartan nor quinapril modified the
production of O2 by NADPH oxidase in these cells.
On cell stimulation, the NADPH oxidase cytosolic subunit
p47phox becomes phosphorylated and migrates to the mem-
brane where it binds to the cytochrome, thus activating the
oxidase to produce O2 .3 Our finding that EXP3179 com-
pletely inhibited p47phox translocation from the cytosolic
fraction to the membrane fraction further supports the possi-
bility that EXP3179 inhibits PMA-dependent O2 production
by blocking the assembly of NADPH oxidase subunits in
phagocytic cells. One of the major mechanisms involved in
the phosphorylation and the translocation of NADPH oxidase
cytosolic subunits involves the activation of PKC.3,24 Thus,
our finding that EXP3179 inhibits PKC stimulation in phago-
cytic cells suggests that EXP3179 is inhibiting NADPH
oxidase by blocking the PKC signaling pathway. In agree-
ment with this, the surface plasmon resonance data show that
EXP3179 interacts with PKC, and the enzymatic assay data
indicate that this metabolite inhibits PKC. Collectively,
these observations allow us to speculate that PKC may be the
target enzyme involved in the ability of EXP3179 to inhibit
NADPH oxidase–dependent O2 production in phagocytic
cells. Although several PKC isoforms have been implicated
in signaling responses of phagocytic cells,25 PKC plays a
selective role in PMA-stimulated phagocytic NADPH oxi-
dase–mediated O2 production.26 Nevertheless, our results
showing that EXP3179 also interacts with PKC, which is
also activated by PMA in phagocytic cells,26 allow us to
suggest that the inhibitory effect of EXP3179 on the PKC in
phagocytic cells is not directed through the specific inhibition
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of only a PKC isoform. Whether the EXP3179 may also
interact with other PKC isoforms need to be determined in
further experiments.
Given that EXP 3179 presents various potentially vasopro-
tective effects,15–18 it is possible to speculate that the pleio-
tropic actions of EXP3179 occur by a mechanism involving
the inhibition of PKC in other vascular cell types. PKC
signaling pathways mediate vascular effects, such as the
cyclooxygenase-2 expression,27 endothelial NO synthase
stimulation,28 regulation of peroxisome proliferator–activated
receptor,29 and platelet activation.30 Additional studies will be
needed to establish the relationship between EXP3179 and
PKC in these vascular cell types. Interestingly, our findings
show that EXP3179 inhibits the NADPH oxidase activity in
endothelial cells. In fact, the activation of the NADPH
oxidase in vascular cells has been shown to also be mediated
through PKC-dependent pathways.31
Our group has demonstrated recently that increased syn-
thesis and secretion of MMP-9 may be consequences of
NADPH oxidase–dependent O2 production in phagocytic
cells.19 In this context, we show that PMA-stimulated MMP-9
secretion by phagocytic cells is inhibited in the presence of
EXP3179. The potential relevance of this finding is related to
both the fact that MMP-9 has been found to be colocalized
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Table. Demographic and Clinical Characteristics of the
Subjects Included in the Study
Patients Characteristics Untreated Losartan Other ARAs ACEIs
Age, y 551 622 572 642
Sex, male/female 63/13 18/2 19/7 27/4
Smoking, % 25 35 19 23
Body mass index, kg/m2 30.00.5 28.00.6 29.90.8 28.20.7
Systolic blood pressure,
mm Hg
1451 1404 1333* 1393
Diastolic blood pressure,
mm Hg
901 832* 831* 821*
Mean blood pressure,
mm Hg
1271 1202* 1152* 1192*
Total cholesterol, mmol/L 6.00.1 5.20.2* 5.40.2* 5.30.2*
LDL cholesterol, mmol/L 4.10.1 3.30.1* 3.50.1* 3.50.1*
HDL cholesterol, mmol/L 1.30.1 1.30.1 1.30.1 1.20.1
Glucose, mg/dL 1042 1044 1095 1156
Triglycerides, mmol/L 1.40.1 1.20.1 1.50.2 1.40.1
MMP-9, ng/mL 12.70.8 8.81.0* 11.91.2 13.11.2
HDL indicates high-density lipoprotein; LDL, low-density lipoprotein.
*P0.05 vs nontreated antihypertensive patients.
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with NADPH oxidase components in macrophage-rich areas
in endarterectomies from atherosclerotic patients19 and the
findings that support a role for MMP-9 in the development of
the plaque.32,33
The clinical meaning of the in vitro observations here
reported is underlined by our observations in hypertensive
patients. We show, for the first time, that patients treated with
losartan exhibit lower values of NADPH oxidase–dependent
O2 production than untreated hypertensives. Because no
changes in this parameter were observed either in patients
treated with other ARAs or in patients treated with ACEIs, we
can speculate that the observed effect in losartan-treated
patients is independent of angiotensin II and the AT1R, thus
reinforcing the potential contribution of EXP3179 to the
above findings.
Finally, we found that hypertensive patients treated with
losartan exhibited lower plasma levels of MMP-9 than
untreated hypertensives and hypertensive patients treated
with other ARAs or ACEIs. In addition, we found a signifi-
cant positive bivariate correlation between phagocytic
NADPH oxidase–dependent O2 production and plasma
levels of MMP-9 in the whole population of hypertensive
patients. Nevertheless, we cannot discard the contribution of
other vascular cells, including endothelial cells and smooth
muscle cells, on the generation of MMP-9.34,35 Collectively,
these findings support the possibility that reduced MMP-9
might be an additional beneficial effect of losartan in hyper-
tension, likely attributed to the ability of its EXP3179
metabolite to inhibit phagocytic NADPH oxidase–dependent
O2 production. This specific property of losartan may be
involved in its capacity to inhibit experimental atherosclero-
sis,36 as well as to prevent ischemic atherosclerotic events in
hypertensive patients.37
Perspectives
Albeit preliminary, these data suggest that EXP3179 acts as
an inhibitor of NADPH oxidase, namely in phagocytic cells,
by a potential mechanism that targets the PKC signaling
pathway. Furthermore, the observed effects of EXP3179 on
MMP-9 secretion from phagocytic cells might be down-
stream effectors of PKC inhibition. Thus, it is proposed that
EXP3179 can be a specific mediator of the ability of losartan
to reduce cell-mediated oxidative stress in hypertension.
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ONLINE SUPPLEMENT 
Losartan metabolite EXP3179 blocks phagocytic NADPH oxidase-mediated 
superoxide production by inhibiting PKC. Potential clinical implications in 
hypertension. 
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EXPANDED METHODS 
 
NADPH oxidase activity in endothelial cells 
In order to analyze the effect of the EXP3179 on NADPH oxidase acivity in non-
phagocytic cells, endothelial cell line (Eahy926) was employed. Cells were maintained 
in DMEM supplemented with fetal calf serum (FCS) 10%, glutamine 4 mol/L, sodium 
piruvate 1 mmol/L, penicilin 100 U/mL and streptomycin 100 µg/mL to reach 80-90% 
confluence at 37 ºC in a humidified enviroment with 5% CO2. Before four hours of 
stimulation with PMA 3.2x10-6 mol/L, cells were preincubated with EXP3179 100 
µmol/L during 30 min. Cells were then scrapped and homogeneized on ice. Protein 
concentration was measured by using the Lowry method. 
Chemiluminscence assays with lucigenin 5 µmol/L and NADPH 0.1 mmol/L were 
used to measure NADPH oxidase activity in 15 µg of protein homogenates. The 
reaction was started by addition of lucigenin to protein homogenates in a final volume 
of 300 µL. Luminescence was measured 5 minutes in a luminometer. A buffer blank 
was substracted from each reading. The value of the area under the curve was used to 
quantify chemiluminescence. Data are expressed as relative light units produced per 
second. 
 
p47phox translocation experiments 
In order to analyze the effect of the EXP3179 on a direct index of NADPH oxidase 
activation, we analyzed the effect of this metabolite on the translocation of p47phox 
from cytosol to membranes. PBMCs (5x106 cells) were stimulated with PMA 3.2 
µmol/L in the presence (20 minutes of preincubation) of EXP3179 100 µmol/L. After 
15 minutes cells were centrifuged at 200g for 5 minutes and resuspended in 1 mL of 
Tris buffer saline (Tris 10 mmol/L pH 8, NaCl 150 mmol/L) containing a protease 
inhibitor cocktail Complete (Roche). Then, cells were centrifuged at 2000g for 10 
minutes. The supernatant was collected and centrifuged at 100000g for 60 minutes at 
4°C. The supernatant, which corresponded to the cytoplasmatic fraction, was mixed 
with loading buffer (Tris 125 mmol/L, SDS 4%, glycerol 20%, β-Mercaptoethanol 10% 
and Bromophenol Blue 0.0125%). The pellet, which corresponded to the membrane 
fraction, was resuspended with loading buffer in the same volume as cytoplasmatic 
fraction. 
p47phox subunit expression was quantified by Western blot as previously published.1 
Expression of the housekeeping protein β-actin was also evaluated. Antibodies were 
purchased from Santa Cruz Biotechnology. 
 
Determination of MMP-9 levels 
A sandwich ELISA (Amersham Biosciences) was used to determine MMP-9 levels in 
plasma samples from the patients and in cultured cells supernatant as previously 
published.2 Briefly, MMP-9 secretion was analyzed both in human PBMCs (1.25x106 
cells) or in monocytes (2.5x105 cells) previously isolated from PBMCs by using the 
MACS Column Technology and CD14 MicroBeads (Miltenyi Biotech). In both cases, 
cells were plated in a 96-well plate for 16 hours. Cells were preincubated for 20 minutes 
with EXP3179 100 µmol/L before stimulation with PMA 64 nmol/L. MMP-9 was 
determined in the supernatants 24 hours later. 
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Determination of PKC activity 
PKC activity was determined by a non-radioactive ELISA (Assay Designs) in PMA-
stimulated cellular homogenates of PBMCs. PBMCs (5x106 cells) were preincubated 
for 20 minutes with EXP3179 100 µmol/L before stimulation with PMA 64 nmol/L. 
After 10 minutes of stimulation, cells were centrifuged at 300g for 10 minutes at 4°C, 
and washed with cold PBS pH 7.4. After adding 300 µL of lysis buffer (MOPS 20 
mmol/L, β-glycerolphosphate 50 mmol/L, sodium fluoride 50 mmol/L, sodium 
vanadate 1 mmol/L, EGTA 5 mmol/L, EDTA 2 mmol/L, NP40 1%, dithiothreitol 1 
mmol/L, benzamidine 1 mmol/L, phenylmethanesulphonylfluoride 1 mmol/L, leupeptin 
10 µg/mL and aprotinin 10 µg/mL) containing a protease inhibitor cocktail Complete 
(Roche), the mixture were incubated for 10 minutes on ice. After centrifugation at 
15000g for 15 minutes at 4°C, the supernatant, that constituted the cytosolic fraction, 
was transferred to a pre-chilled tube to be stored at -70ºC. 
By using the same ELISA, we studied the inhibitory effect of EXP3179 on the 
enzymatic activity of the human recombinant PKCα and PKCβ (SIGMA). In this study, 
the specific inhibitor of PKC, bisindolyl maleimide (BIS) I 1 µmol/L, was used as a 
positive control. 
 
Biomolecular interactions analysis. 
Interaction experiments were performed using surface plasmon resonance (SPR) 
technology in a BIAcore X Biosensor. A PKCα surface (21,000 RU) was prepared with 
the amine coupling Kit. Anti-β2 microglobulin antibody was immobilized on flow 
channel 1 in order to create a reference surface. EXP3179 at concentrations of 0, 2, 4, 8, 
16 and 32 µmol/L was injected in duplicate in HEPES 10 mmol/L, NaCl 150 mmol/L, 
Tween-20 0.005% (v/v) (pH 7.4) at a flow of 30 µL/min and allowing an association 
time of 60 s. Mass transport limitation effects were excluded. BIS I 50 µmol/L was also 
injected onto the PKC surface and a clear and specific binding signal was detected (data 
not shown). Thus, this system is suitable for checking the interaction between PCK and 
its ligands. Kinetic and affinity analysis were performed using BIAEVALUATION 
software 3.2RC1. Finally, we analyzed also the interaction of human recombinant 
PKCβ (21,000 RU) with EXP3179 32 µmol/L. 
 
Statistical analysis 
Data are expressed as mean±SEM. Differences among groups were assessed by one-
way ANOVA once normality had been demonstrated and a Scheffé post hoc test was 
used to examine differences between groups when significance was achieved; otherwise 
a Kruskal-Wallis followed by a Mann-Whitney U test was used. Pearson correlation test 
was used to assess correlation between plasma MMP-9 levels and NADPH oxidase-
dependent ·O2- production. The calculations were performed using the SPSS/Windows 
version 13.0 statistical package. Statistical significance was established as P<0.05. 
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